Underexpression of HOXA11 Is Associated with Treatment Resistance and Poor Prognosis in Glioblastoma
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Purpose Homeobox (HOX) genes are essential developmental regulators that should normally be in the silenced state in an adult brain. The aberrant expression of HOX genes has been associated with the prognosis of many cancer types, including glioblastoma (GBM). This study examined the identity and role of HOX genes affecting GBM prognosis and treatment resistance. Materials and Methods The full series of HOX genes of five pairs of initial and recurrent human GBM samples were screened by microarray analysis to determine the most plausible candidate responsible for GBM prognosis. Another 20 newly diagnosed GBM samples were used for prognostic validation. In vitro experiments were performed to confirm the role of HOX in treatment resistance. Mediators involved in HOX gene regulation were searched using differentially expressed gene analysis, gene set enrichment tests, and network analysis. Results The underexpression of HOXA11 was identified as a consistent signature for a poor prognosis among the HOX genes. The overall survival of the GBM patients indicated a significantly favorable prognosis in patients with high HOXA11 expression (31±15.3 months) compared to the prognoses in those with low HOXA11 expression (18±7.3 months, p=0.03). When HOXA11 was suppressed in the GBM cell lines, the anticancer effect of radiotherapy and/or temozolomide declined. In addition, five candidate mediators (TGFBR2, CRIM1, TXNIP, DPYSL2, and CRMP1) that may confer an oncologic effect after HOXA11 suppression were identified. Conclusion The treatment resistance induced by the underexpression of HOXA11 can contribute to a poor prognosis in GBM. Further investigation will be needed to confirm the value of HOXA11 as a potential target for overcoming the treatment resistance by developing chemo- or radiosensitizers.
Abstract
Purpose Homeobox (HOX) genes are essential developmental regulators that should normally be in the silenced state in an adult brain. The aberrant expression of HOX genes has been associated with the prognosis of many cancer types, including glioblastoma (GBM). This study examined the identity and role of HOX genes affecting GBM prognosis and treatment resistance. Materials and Methods The full series of HOX genes of five pairs of initial and recurrent human GBM samples were screened by microarray analysis to determine the most plausible candidate responsible for GBM prognosis. Another 20 newly diagnosed GBM samples were used for prognostic validation. In vitro experiments were performed to confirm the role of HOX in treatment resistance. Mediators involved in HOX gene regulation were searched using differentially expressed gene analysis, gene set enrichment tests, and network analysis. Results The underexpression of HOXA11 was identified as a consistent signature for a poor prognosis among the HOX genes. The overall survival of the GBM patients indicated a significantly favorable prognosis in patients with high HOXA11 expression (31±15.3 months) compared to the prognoses in those with low HOXA11 expression (18±7.3 months, p=0.03). When HOXA11 was suppressed in the GBM cell lines, the anticancer effect of radiotherapy and/or temozolomide declined. In addition, five candidate mediators (TGFBR2, CRIM1, TXNIP, DPYSL2, and CRMP1) that may confer an oncologic effect after HOXA11 suppression were identified. Conclusion The treatment resistance induced by the underexpression of HOXA11 can contribute to a poor prognosis in GBM. Further investigation will be needed to confirm the value of HOXA11 as a potential target for overcoming the treatment resistance by developing chemo- or radiosensitizers.
참고문헌 (52)
- Shah N, "The Hox genes and their roles in oncogenesis", Nat Rev Cancer, 10, pp.361~371 (2010)
- Takahashi Y, "Expression profiles of 39 HOX genes in normal human adult organs and anaplastic thyroid cancer cell lines by quantitative real-time RT-PCR system", Exp Cell Res, 293, pp.144~153 (2004)
- Abate-Shen C, "Deregulated homeobox gene expression in cancer: cause or consequence?", Nat Rev Cancer, 2, pp.777~785 (2002)
- Abdel-Fattah R, "Differential expression of HOX genes in neoplastic and non-neoplastic human astrocytes", J Pathol, 209, pp.15~24 (2006)
- Bodey B, "Immunocytochemical detection of the homeobox B3, B4, and C6 gene products in childhood medulloblastomas", primitive neuroectodermal tumors, 2000, pp.20, 1769~1780
- Buccoliero AM, "Hox-D genes expression in pediatric low-grade gliomas : real-time-PCR study", Cell Mol Neurobiol, 29, pp.1~6 (2009)
- Ferrando AA, "Gene expression signatures in MLL-rearranged T-lineage and B-precursor acute leukemias : dominance of HOX dysregulation", Blood, 102, pp.262~268 (2003)
- Miao J, "HOXB13 promotes ovarian cancer progression", Proc Natl Acad Sci U S A, 104, pp.17093~17098 (2007)
- Murat A, "Stem cell-related"self-renewal"signature and high epidermal growth factor receptor expression associated with resistance to concomitant chemoradiotherapy in glioblastoma", J Clin Oncol, 26, pp.3015~3024 (2008)
- Wang Z, "The prognostic biomarkers HOXB13, IL17BR, and CHDH are regulated by estrogen in breast cancer", Clin Cancer Res, 13, pp.6327~6334 (2007)
- Gaspar N, "MGMT-independent temozolomide resistance in pediatric glioblastoma cells associated with a PI3-kinasemediated HOX", stem cell gene signature, 2010, pp.70, 9243~9252
- Kim JW, "HOXA10 is associated with temozolomide resistance through regulation of the homologous recombinant DNA repair pathway in glioblastoma cell lines", Genes Cancer, 5, pp.165~174 (2014)
- Kim KJ, "Transcriptional regulation of MDR-1 by HOXC6 in multidrugresistant cells", Oncogene, 32, pp.3339~3349 (2013)
- Bao S, "Glioma stem cells promote radioresistance by preferential activation of the DNA damage response", Nature, 444, pp.756~760 (2006)
- Chen J, "A restricted cell population propagates glioblastoma growth after chemotherapy", Nature, 488, pp.522~526 (2012)
- Atkinson SP, "Epigenetic marking prepares the human HOXA cluster for activation during differentiation of pluripotent cells", Stem Cells, 26, pp.1174~1185 (2008)
- Kwon SM, "Recurrent glioblastomas reveal molecular subtypes associated with mechanistic implications of drug-resistance", PLoS One, 10, pp.e0140528~ (2015)
- Reich M, "GenePattern 2.0", Nat Genet, 38, pp.500~501 (2006)
- Huang DW, "Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources", Nat Protoc, 4, pp.44~57 (2009)
- Warde-Farley D, "The GeneMANIA prediction server: biological network integration for gene prioritization and predicting gene function", Nucleic Acids Res, 38, pp.W214~W220 (2010)
- Hueber SD, "Shaping segments : Hox gene function in the genomic age", Bioessays, 30, pp.965~979 (2008)
- Ohgo S, "Analysis of hoxa11 and hoxa13 expression during patternless limb regeneration in Xenopus", Dev Biol, 338, pp.148~157 (2010)
- Argiropoulos B, "Hox genes in hematopoiesis and leukemogenesis", Oncogene, 26, pp.6766~6776 (2007)
- Bahrani-Mostafavi Z, "Correlation analysis of HOX, ErbB and IGFBP family gene expression in ovarian cancer", Cancer Invest, 26, pp.990~998 (2008)
- Cillo C, "HOX gene expression in normal and neoplastic human kidney", Int J Cancer, 51, pp.892~897 (1992)
- De Vita G, "Expression of homeobox-containing genes in primary and metastatic colorectal cancer", Eur J Cancer, 29, pp.887~893 (1993)
- Costa BM, "Reversing HOXA9 oncogene activation by PI3K inhibition : epigenetic mechanism and prognostic significance in human glioblastoma", Cancer Res, 70, pp.453~462 (2010)
- Lim JY, "Overexpression of miR-196b and HOXA10 characterize a poor-prognosis gastric cancer subtype", World J Gastroenterol, 19, pp.7078~7088 (2013)
- Carrio M, "Homeobox D10induces phenotypic reversion of breast tumor cells in a threedimensional culture model", Cancer Res, 65, pp.7177~7185 (2005)
- Petrini M, "HOXB1 restored expression promotes apoptosis and differentiation in the HL60 leukemic cell line", Cancer Cell Int, 13, pp.101~ (2013)
- Rhoads K, "A role for Hox A5 in regulating angiogenesis and vascular patterning", Lymphat Res Biol, 3, pp.240~252 (2005)
- Carrera M, "HOXA10 controls proliferation, migration and invasion in oral squamous cell carcinoma", Int J Clin Exp Pathol, 8, pp.3613~3623 (2015)
- Cui XP, "HOXA10 promotes cell invasion and MMP-3 expression via TGFbeta2-mediated activation of the p38 MAPK pathway in pancreatic cancer cells", Dig Dis Sci, 59, pp.1442~1451 (2014)
- Kurscheid S, "Chromosome 7 gain and DNA hypermethylation at the HOXA10 locus are associated with expression of a stem cell related HOX-signature in glioblastoma", Genome Biol, 16, pp.16~ (2015)
- Li B, "HoxA10induces proliferation in human prostate carcinoma PC-3 cell line", Cell Biochem Biophys, 70, pp.1363~1368 (2014)
- Liborio-Kimura TN, "miR-494 represses HOXA10 expression and inhibits cell proliferation in oral cancer", Oral Oncol, 51, pp.151~157 (2015)
- Oue N, "Clinicopathologic and molecular characteristics of gastric cancer showing gastric and intestinal mucin phenotype", Cancer Sci, 106, pp.951~958 (2015)
- Xiao ZD, "miR-218 modulate hepatocellular carcinoma cell proliferation through PTEN", AKT, Int J Clin Exp Pathol, pp.2014, 7[DOI]
- Zhang HY, "Activation of ARK5", miR-1181, Oncol Rep, pp.2015, 34[DOI]
- Zhang L, "Upregulation HOXA10 homeobox gene in endometrial cancer : role in cell cycle regulation", Med Oncol, 31, pp.52~ (2014)
- Bai Y, "HOXA11gene is hypermethylation and aberrant expression in gastric cancer", Cancer Cell Int, 14, pp.79~ (2014)
- Cui Y, "Epigenetic changes and functional study of HOXA11 in human gastric cancer", Epigenomics, 7, pp.201~213 (2015)
- Fiegl H, "HOXA11 DNA methylation : a novel prognostic biomarker in ovarian cancer", Int J Cancer, 123, pp.725~729 (2008)
- Hwang JA, "HOXA11 hypermethylation is associated with progression of non-small cell lung cancer", Oncotarget, 4, pp.2317~2325 (2013)
- Laffaire J, "Methylation profiling identifies 2 groups of gliomas according to their tumorigenesis", Neuro Oncol, 13, pp.84~98 (2011)
- Martinez R, "A microarray-based DNA methylation study of glioblastoma multiforme", Epigenetics, 4, pp.255~264 (2009)
- Skiriute D, "Promoter methylation of AREG, HOXA11, hMLH1, NDRG2, NPTX2 and Tes genes in glioblastoma", J Neurooncol, 113, pp.441~449 (2013)
- Fang F, "The novel, small-molecule DNA methylation inhibitor SGI-110 as an ovarian cancer chemosensitizer", Clin Cancer Res, 20, pp.6504~6516 (2014)
- Matei D, "Epigenetic resensitization to platinum in ovarian cancer", Cancer Res, 72, pp.2197~2205 (2012)
- Shih JY, "Collapsin response mediator protein-1 : a novel invasion-suppressor gene", Clin Exp Metastasis, 20, pp.69~76 (2003)
- Mukherjee J, "Loss of collapsin response mediator protein1, as detected by iTRAQ analysis, promotes invasion of human gliomas expressing mutant EGFRvIII", Cancer Res, 69, pp.8545~8554 (2009)
- Yilmaz N, "HOXA11 and MMP2 gene expression in uterosacral ligaments of women with pelvic organ prolapse", J Turk Ger Gynecol Assoc, 15, pp.104~108 (2014)
